Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04560075 · ClinicalTrials.gov registry record · NA
Text 2 Connect- Texting Intervention for Mental Health Treatment Utilization
A NA study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT04560075: Completed NA study, sponsored by University of Pittsburgh.
NCT04560075 is a NA study that has completed, run by University of Pittsburgh. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04560075, a NA study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
Text2Connect (T2C) proposes to test a text-based intervention designed to improve engagement with mental health treatment.
Primary Outcome
Participant's engagement with the T2C intervention will be assessed via their response rate to SMS prompts, as the primary outcome of Text2Connect Phase 2. "High" engagement with T2C will be rated as \>70% response rate. All Intervention participants (n=34) received text-message check-ins with question: "How would you rate your emotional health this past week?" on a likert scale of: 1=excellent; 2=very good; 3=good;4=fair; 5=poor. Participants who did not respond to this message initially were
Interventions
- BEHAVIORAL Text2Connect
- BEHAVIORAL Psychoeducational Videos (PE) Only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2021-01-31 |
| Phase | NA |
What the finished NCT04560075 record still lists
NCT04560075 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Text2Connect is the first listed.
NCT04560075 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04560075 about?
NCT04560075 is a clinical study titled "Text 2 Connect- Texting Intervention for Mental Health Treatment Utilization". Text2Connect (T2C) proposes to test a text-based intervention designed to improve engagement with mental health treatment.
What is the current status of trial NCT04560075?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2020-10-01. Estimated completion is 2021-01-31.
What interventions are being tested in trial NCT04560075?
The interventions under investigation include: Text2Connect (BEHAVIORAL), Psychoeducational Videos (PE) Only (BEHAVIORAL).
Who is sponsoring clinical trial NCT04560075?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04560075's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI